Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus

New England Journal of Medicine

Volumn 349, Issue 9, 2003, Pages 837-846

  Lawrence, Jody ^a,f   Mayers, Douglas L ^g   Hullsiek, Katherine Huppler ^b   Collins, Gary ^b   Abrams, Donald I ^a   Reisler, Ronald B ^c   Crane, Lawrence R ^g   Schmetter, Barry S ^d   Dionne, Thomas J ^e   Saldanha, Jennifer M ^g   Jones, Michael C ^a   Baxter, John D ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^e Washington Regional AIDS Program   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; QUALITY OF LIFE; TREATMENT WITHDRAWAL; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RNA, VIRAL;

EID: 0042431969     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa035103     Document Type: Article

References (22)

1. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000;181:946-53.
2. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002;16:201-7.
3. Barbour JD, Wrin T, Grant RM, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002;76:11104-12.
4. Kantor R, Fessel WJ, Zolopa AP, et al. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob Agents Chemother 2002;46:1086-92.
5. Youle M, Janossy G, Turnbull W, et al. Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. AIDS 2000;14:1717-20.
6. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:F123-F127.
7. Delaugerre C, Valantin MA, Mouroux M, et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 2001;15:2189-91.
8. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-80.
9. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000;14:2857-67.
10. Tebas P, Henry K, Mondy K, et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. J Infect Dis 2002;186:851-4. [Erratum, J Infect Dis 2002;186:1199.]
11. Deeks SG, Wrin T, Hoh R, et al. Virologic and immunologic evaluation of structured treatment interruptions in HIV-1 infected patients experiencing long-term virologic failure. Presented at the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000. abstract.
12. Izopet J, Massip P, Souyris C, et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 2000; 14:2247-55.
13. Deeks SG, Grant RM, Wrin T, et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 2003;17:361-70.
14. Ruiz L, Ribera E, Bonjoch A, et al. Virological and immunological benefit of a salvage therapy that includes kaletra plus fortovase preceded or not by antiretroviral therapy interruption in advanced HIV-infected patients with multidrug resistance mutations (48 weeks follow-up). Antiviral Ther 2002;7: Suppl 1:S126. abstract.
15. Katlama C, Dominguez S, Duvivier C, et al. Long-term benefit of treatment interruption in salvage therapy (GIGHAART ANRS 097). Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10-14, 2003. abstract.
16. Green LA, Rhame FS, Price RW, et al. Experience with a cross-study endpoint review committee for AIDS clinical trials. AIDS 1998;12:1983-90.
17. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19.
18. Ware J, Kosinski M, Keller S. SF-12: how to score the SF-12 Physical and Mental Health Summary Scales. 3rd ed. Lincoln, R.I.: QualityMetric, 2000.
19. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002: recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51(RR-8):1-52.
20. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWK Recomm Rep 1999;48(RR-10):1-59, 61-6.
21. Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002;16:579-88.
22. Lundgren JD, Vella S, Paddam L, et al. Interruption/stopping antiretroviral therapy and the risk of clinical disease: results from the EuroSIDA Study. Presented at the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, February 24-28, 2002. abstract.